The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to Determine the Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile
Helsinki University Central Hospital
250 participants
Dec 10, 2021
INTERVENTIONAL
Conditions
Summary
This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
ALK
MEK1, MEK2
Hedgehog
HER2
NTRK/ ROS1, ALK
PD-L1
BRAF V600
KIT/BRAF, RET
AR
CDK4/6
MET ex14
RAF
MEK1, MEK2
RAF, MEK1, MEK2
FGFR2
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05159245